Fang JH, et al. - In this investigation, researchers ascertained if the vascular pattern, named VETC (Vessels that Encapsulate Tumor Clusters), could predict sorafenib [the most recommended first-line systemic therapy for advanced hepatocellular carcinoma (HCC)] benefit. The survival benefit of sorafenib treatment has been investigated for patients with or without the pattern of VETC (VETC⁺/VETC^–). Findings revealed that sorafenib prolongs the survival of patients with VETC⁺, but not VETC^–. For HCC, VETC pattern can act as a predictor of sorafenib benefit.